Exagen Inc Stock

$1.93-0.01 (-0.52%)
Updated Jul 12, 2024
XGN Price
Fair Value Price
Market Cap
52 Week Low
52 Week High
Dividend Yield
Gross Margin
Operating Margin
Profit Margin
Debt to Equity
Operating Cash Flow
Next Earnings
Aug 5, 2024
Next Dividend

XGN Overview

Exagen Inc. develops and commercializes various testing products based on its cell-bound complement activation products technology under the AVISE brand in the United States. It enables rheumatologists to care for patients through the diagnosis, prognosis, and monitoring of autoimmune and autoimmune-related diseases, including systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). Its lead testing product is AVISE CTD that enables differential diagnosis for patients presenting with symptoms indicative of various connective tissue diseases (CTDs) and other related diseases with overlapping symptoms. The company offers AVISE Lupus that measures activation of the complement system by quantifying the level of B-cell C4d and erythrocyte bound C4d in the patient's blood; and AVISE APS, which consists of a panel of autoantibody tests that aids in the diagnosis and management of APS. In addition, it provides AVISE SLE Prognostic, a panel of autoantibodies for assessing the potential for complications affecting the kidney, brain, and cardiovascular system; AVISE Vasculitis AAV, which utilizes a testing panel of individual analytes to provide physicians with results in the assessment and monitoring of anti-neutrophil cytoplasmic antibody and associated vasculitis; AVISE Anti-CarP test, which identifies RA patients with severe disease; and AVISE PC4d to measure platelet- bound C4d. Further, the company offers AVISE SLE Monitor, a biomarker blood test; AVISE MTX, a patented and validated blood test; and AVISE HCQ, a blood test to monitor levels of hydroxychloroquine. It has a research collaboration and license agreement with Allegheny Health Network (AHN) Research Institute to develop novel patented biomarkers. The company was formerly known as Exagen Diagnostics, Inc. and changed its name to Exagen Inc. in January 2019. Exagen Inc. was incorporated in 2002 and is headquartered in Vista, California.

Zen Score

Industry Average (25)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how XGN scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.

Due Diligence Checks

XGN is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
XGN is good value based on its book value relative to its share price (1.68x), compared to the US Diagnostics & Research industry average (4.12x)
P/B vs Industry Valuation
XGN is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more XGN due diligence checks available for Premium users.

Be the first to know about important XGN news, forecast changes, insider trades & much more!

XGN News


XGN fair value

Fair Value of XGN stock based on Discounted Cash Flow (DCF)
Fair Value
Undervalued by
XGN is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation

XGN price to earnings (PE)

For valuing profitable companies with steady earnings

XGN price to book (PB)

For valuing companies that are loss-making or have lots of physical asset
XGN is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation

XGN's financial health

Profit margin

Net Income
Profit Margin
XGN's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
XGN's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials

Assets to liabilities

Debt to equity
XGN's short-term assets ($42.40M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
XGN's short-term assets ($42.40M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
XGN's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials

Cash flow

XGN's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials

XGN vs Diagnostic & Research Stocks

TickerMarket Cap1d %P/EP/B

Exagen Stock FAQ

What is Exagen's quote symbol?

(NASDAQ: XGN) Exagen trades on the NASDAQ under the ticker symbol XGN. Exagen stock quotes can also be displayed as NASDAQ: XGN.

If you're new to stock investing, here's how to buy Exagen stock.

What is the 52 week high and low for Exagen (NASDAQ: XGN)?

(NASDAQ: XGN) Exagen's 52-week high was $2.95, and its 52-week low was $1.30. It is currently -34.58% from its 52-week high and 48.46% from its 52-week low.

How much is Exagen stock worth today?

(NASDAQ: XGN) Exagen currently has 17,373,482 outstanding shares. With Exagen stock trading at $1.93 per share, the total value of Exagen stock (market capitalization) is $33.53M.

Exagen stock was originally listed at a price of $18.58 in Sep 19, 2019. If you had invested in Exagen stock at $18.58, your return over the last 4 years would have been -89.61%, for an annualized return of -43.23% (not including any dividends or dividend reinvestments).

How much is Exagen's stock price per share?

(NASDAQ: XGN) Exagen stock price per share is $1.93 today (as of Jul 12, 2024).

What is Exagen's Market Cap?

(NASDAQ: XGN) Exagen's market cap is $33.53M, as of Jul 15, 2024.

Market cap (market capitalization) is the total market value of a publicly traded company's outstanding shares.

Exagen's market cap is calculated by multiplying XGN's current stock price of $1.93 by XGN's total outstanding shares of 17,373,482.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.